It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature
Matilde Pensabene(University of Naples Federico II), Rossella Lauria, Caterina Condello(University of Naples Federico II), Giuseppe Di Lorenzo(Saint Camillus International University of Health and Medical Sciences), Valeria Forestieri(University of Naples Federico II), Mario Giuliano(Regione Campania), Brigida Stanzione(National Cancer Institute), Giuseppe Ciancia(University of Naples Federico II), Immacolata Cozzolino(University of Campania "Luigi Vanvitelli"), Sabino De Placido, Grazia Arpino(University of Naples Federico II), Ivana Cerillo(University of Naples Federico II), Raffaella Ruocco(University of Naples Federico II)
Cited by 21
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282